Detected ·
Crystalys Therapeutics
$130M—
Crystalys Therapeutics closed an oversubscribed $130M Series B financing to advance dotinurad's late-stage global clinical development for gout. The round was led by Frazier Life Sciences, with Wellington Management, HBM Healthcare Investments, and existing investors including AN Venture Partners participating.
- Website
- —
- Amount
- $130 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-11 12:04:25 UTC
- Signal ID
- 4fa6c5ec-1c48-4081-bc67-96649f30b08b
As the API returns it
{
"id": "4fa6c5ec-1c48-4081-bc67-96649f30b08b",
"created_at": "2026-08-11T12:04:25.775304Z",
"company_name": "Crystalys Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/crystalys-therapeutics",
"event_type": "funding",
"funding_amount": 130000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Crystalys Therapeutics closed an oversubscribed $130M Series B financing to advance dotinurad's late-stage global clinical development for gout. The round was led by Frazier Life Sciences, with Wellington Management, HBM Healthcare Investments, and existing investors including AN Venture Partners participating.*"
}